Table 3 Associations of DLR and clinicopathological characteristics
Characteristic | Total n (%) | DLR(n = 88) | P value | |
|---|---|---|---|---|
Low DLR (n = 37) | High DLR (n = 51) | |||
Age, years | 88 (100) | 56.56 ± 13.51 | 57.96 ± 14.33 | 0.646 |
Gender | 88 (100) | 0.896 | ||
Male | 54 (61.4) | 23 (62.2) | 31(60.8) | |
Female | 34 (38.6) | 14 (37.8) | 20 (39.2) | |
BMI, kg/m2 | 88 (100) | 22.10 ± 3.19 | 21.30 ± 2.66 | 0.204 |
Site | 88 (100) | 0.140 | ||
Right | 39 (44.3) | 13 (35.1) | 26 (51.0) | |
Left | 49 (55.7) | 24 (64.9) | 25 (49.0) | |
Tumor size, D/cm | 88 (100) | 4.50 (2.80–6.75) | 5.00 (3.20–6.00) | 0.872 |
Vascular invasion | 88 (100) | 0.863 | ||
No | 39 (44.3) | 16 (43.2) | 23(45.1) | |
Yes | 49 (55.7) | 21 (56.8) | 28 (54.9) | |
Perineural invasion | 88 (100) | |||
No | 28 (31.8) | 11 (29.7) | 17 (33.3) | 0.720 |
Yes | 60 (68.2) | 26 (70.3) | 34 (66.7) | |
T stage | 88 (100) | |||
1–3 | 37 (42.0) | 15 (40.5) | 22 (43.1) | 0.808 |
4 | 51 (58.0) | 22(59.5) | 29 (56.9) | |
N stage | 88 (100) | |||
0 | 40 (45.5) | 17 (45.9) | 23 (45.1) | 0.937 |
1–2 | 48 (54.5) | 20 (54.1) | 28 (54.9) | |
Neoadjuvant treatment | 88 (100) | |||
No | 52 (59.1) | 19 (51.4) | 33 (64.7) | 0.208 |
Yes | 36 (40.9) | 18 (48.6) | 18 (35.3) | |
Differentiation extent | 88 (100) | |||
1 | 13 (14.8) | 4 (10.8) | 9 (17.6) | 0.449 |
2 | 74 (84.1) | 33 (89.2) | 41 (80.4) | |
3 | 1 (1.1) | 0 (0.0) | 1 (2.0) | |
D Dimer | 88 (100) | 0.26 (0.10–0.495) | 1.56 (0.98–3.29) | < 0.001 |
Lymphocyte | 88 (100) | 1.67 ± 0.37 | 1.35 ± 0.43 | < 0.001 |
CEA | 88 (100) | 4.92 (2.27–32.83) | 22.23 (7.60–85.17) | 0.001 |
CA125 | 88 (100) | 12.2 (7.95–21.40) | 24.5 (10.50–53.00) | 0.003 |
CA199 | 88 (100) | 15.9 (4.20–95.45) | 31.10 (12.50–141.90) | 0.069 |